Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Mon Dec 01 2025 10:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
SOLAIRIA‑1 and SOLAIRIA‑2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the promise of programmable biology SOMERVILLE, Mass., December 1, 2025— Generate:Biomedicines (“Generate”) tod
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.